PATENT CLAIM ANALYSIS

Application Number: 16035774
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "252160"]

Abstract:
The present invention relates to a pharmaceutical combination comprising, separately or together, (1) a first agent which is an ALK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof. The invention further relates the use of such combination in the treatment or prevention of proliferative diseases.

Claim (Index 20):
Use of a pharmaceutical combination according to  claim 1  or a pharmaceutical composition of  claim 9  for the preparation of a medicament for treating a proliferative disease.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 95.0
- Lexical Diversity: 1.61905
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14308088', '12573358', '14214048', '14651297', '13403976']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7287468672249449
- 35 USC 102 Novelty (BERT): 0.5136001110622197
- Combined Prediction Score: 0.7072321916086725
- Mean Citation Score: 230.988524
- Max Citation Score: 237.77817
- Similarity Product: 154.17509821055887

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test